Hypericin maintians PDX1 expression via the Erk pathway and protects islet β-cells against glucotoxicity and...

Area of Science:

• Endocrinology
• Pharmacology
• Cell Biology

Background:

• Islet beta-cell mass reduction is linked to diabetes development and progression.
• Protecting beta cells is crucial for diabetes prevention and treatment.

Purpose of the Study:

• To investigate the protective effects of non-photoactivated hypericin on beta cells in vitro and in vivo.
• To evaluate hypericin's potential as an anti-diabetic agent.

Main Methods:

• In vitro studies using INS-1 cells exposed to high glucose and fatty acids.
• In vivo studies using high-fat/high-sucrose (HFHS)-fed mice for prophylactic and therapeutic assessments.
• Assessed cell viability, apoptosis, nitric oxide (NO) production, pancreatic duodenal homeobox-1 (PDX1) expression, Erk activity, oxidative stress, blood glucose, glucose/insulin tolerance, and insulin levels.

Main Results:

• Hypericin improved INS-1 cell viability by inhibiting apoptosis and NO production under glucotoxicity and lipotoxicity.
• Hypericin attenuated PDX1 reduction and Erk activity decrease in beta cells.
• In HFHS-fed mice, hypericin inhibited beta-cell apoptosis, enhanced antioxidant capacity, maintained beta-cell mass, and improved glucose/insulin homeostasis.
• Hypericin treatment reduced fasting blood glucose, improved glucose and insulin intolerance, and alleviated hyperinsulinemia.

Conclusions:

• Non-photoactivated hypericin demonstrates significant protective effects against beta-cell loss and dysfunction.
• Hypericin exhibits both preventive and therapeutic potential for type II diabetes.
• Hypericin shows promise as a future anti-diabetic drug candidate.